340 related articles for article (PubMed ID: 31432419)
1. Deployment of Label-Free Quantitative Olfactory Proteomics to Detect Cerebrospinal Fluid Biomarker Candidates in Synucleinopathies.
Lachén-Montes M; González-Morales A; Fernández-Irigoyen J; Santamaría E
Methods Mol Biol; 2019; 2044():273-289. PubMed ID: 31432419
[TBL] [Abstract][Full Text] [Related]
2. Unveiling the olfactory proteostatic disarrangement in Parkinson's disease by proteome-wide profiling.
Lachén-Montes M; González-Morales A; Iloro I; Elortza F; Ferrer I; Gveric D; Fernández-Irigoyen J; Santamaría E
Neurobiol Aging; 2019 Jan; 73():123-134. PubMed ID: 30342273
[TBL] [Abstract][Full Text] [Related]
3. Essential Features and Use Cases of the Cerebrospinal Fluid Proteome Resource (CSF-PR).
Guldbrandsen A; Farag YM; Lereim RR; Berven FS; Barsnes H
Methods Mol Biol; 2019; 2044():377-391. PubMed ID: 31432427
[TBL] [Abstract][Full Text] [Related]
4. A Versatile Workflow for Cerebrospinal Fluid Proteomic Analysis with Mass Spectrometry: A Matter of Choice between Deep Coverage and Sample Throughput.
Macron C; Núñez Galindo A; Cominetti O; Dayon L
Methods Mol Biol; 2019; 2044():129-154. PubMed ID: 31432411
[TBL] [Abstract][Full Text] [Related]
5. Tackling the Biological Meaning of the Human Olfactory Bulb Dyshomeostatic Proteome across Neurological Disorders: An Integrative Bioinformatic Approach.
Cartas-Cejudo P; Lachén-Montes M; Fernández-Irigoyen J; Santamaría E
Int J Mol Sci; 2021 Oct; 22(21):. PubMed ID: 34768771
[TBL] [Abstract][Full Text] [Related]
6. Top-Down Proteomics Applied to Human Cerebrospinal Fluid.
Gay M; Sánchez-Jiménez E; Villarreal L; Vilanova M; Huguet R; Arauz-Garofalo G; Díaz-Lobo M; López-Ferrer D; Vilaseca M
Methods Mol Biol; 2019; 2044():193-219. PubMed ID: 31432414
[TBL] [Abstract][Full Text] [Related]
7. Determination of Cerebrospinal Fluid Proteome Variations by Isobaric Labeling Coupled with Strong Cation-Exchange Chromatography and Tandem Mass Spectrometry.
Lachén-Montes M; González-Morales A; Fernández-Irigoyen J; Santamaría E
Methods Mol Biol; 2019; 2044():155-168. PubMed ID: 31432412
[TBL] [Abstract][Full Text] [Related]
8. Olfactory bulb proteome dynamics during the progression of sporadic Alzheimer's disease: identification of common and distinct olfactory targets across Alzheimer-related co-pathologies.
Zelaya MV; Pérez-Valderrama E; de Morentin XM; Tuñon T; Ferrer I; Luquin MR; Fernandez-Irigoyen J; Santamaría E
Oncotarget; 2015 Nov; 6(37):39437-56. PubMed ID: 26517091
[TBL] [Abstract][Full Text] [Related]
9. Analyzing Cerebrospinal Fluid Proteomes to Characterize Central Nervous System Disorders: A Highly Automated Mass Spectrometry-Based Pipeline for Biomarker Discovery.
Núñez Galindo A; Macron C; Cominetti O; Dayon L
Methods Mol Biol; 2019; 1959():89-112. PubMed ID: 30852817
[TBL] [Abstract][Full Text] [Related]
10. Biological confounders for the values of cerebrospinal fluid proteins in Parkinson's disease and related disorders.
Mollenhauer B; Parnetti L; Rektorova I; Kramberger MG; Pikkarainen M; Schulz-Schaeffer WJ; Aarsland D; Svenningsson P; Farotti L; Verbeek MM; Schlossmacher MG
J Neurochem; 2016 Oct; 139 Suppl 1():290-317. PubMed ID: 26452984
[TBL] [Abstract][Full Text] [Related]
11. Proteomic analysis of cerebrospinal fluid extracellular vesicles: a comprehensive dataset.
Chiasserini D; van Weering JR; Piersma SR; Pham TV; Malekzadeh A; Teunissen CE; de Wit H; Jiménez CR
J Proteomics; 2014 Jun; 106():191-204. PubMed ID: 24769233
[TBL] [Abstract][Full Text] [Related]
12. Peptidomic Workflow Applied to Cerebrospinal Fluid Analysis.
Ziganshin RH; Kovalchuk SI; Azarkin IV
Methods Mol Biol; 2019; 2044():111-118. PubMed ID: 31432409
[TBL] [Abstract][Full Text] [Related]
13. Proteomics of the Human Olfactory Tract.
Dammalli M; Dey G; Kumar M; Madugundu AK; Gopalakrishnan L; Gowrishankar BS; Mahadevan A; Shankar SK; Prasad TSK
OMICS; 2018 Jan; 22(1):77-87. PubMed ID: 29356628
[TBL] [Abstract][Full Text] [Related]
14. Label-Free LC-MS/MS Proteomic Analysis of Cerebrospinal Fluid Identifies Protein/Pathway Alterations and Candidate Biomarkers for Amyotrophic Lateral Sclerosis.
Collins MA; An J; Hood BL; Conrads TP; Bowser RP
J Proteome Res; 2015 Nov; 14(11):4486-501. PubMed ID: 26401960
[TBL] [Abstract][Full Text] [Related]
15. Proteomic atlas of the human olfactory bulb.
Fernández-Irigoyen J; Corrales FJ; Santamaría E
J Proteomics; 2012 Jul; 75(13):4005-16. PubMed ID: 22609191
[TBL] [Abstract][Full Text] [Related]
16. The Human Brain Proteome Project: Biological and Technological Challenges.
Fernández-Irigoyen J; Corrales F; Santamaría E
Methods Mol Biol; 2019; 2044():3-23. PubMed ID: 31432403
[TBL] [Abstract][Full Text] [Related]
17. Quantitative label-free proteomics for discovery of biomarkers in cerebrospinal fluid: assessment of technical and inter-individual variation.
Perrin RJ; Payton JE; Malone JP; Gilmore P; Davis AE; Xiong C; Fagan AM; Townsend RR; Holtzman DM
PLoS One; 2013; 8(5):e64314. PubMed ID: 23700471
[TBL] [Abstract][Full Text] [Related]
18. Olfactory bulb alpha-synucleinopathy has high specificity and sensitivity for Lewy body disorders.
Beach TG; White CL; Hladik CL; Sabbagh MN; Connor DJ; Shill HA; Sue LI; Sasse J; Bachalakuri J; Henry-Watson J; Akiyama H; Adler CH;
Acta Neuropathol; 2009 Feb; 117(2):169-74. PubMed ID: 18982334
[TBL] [Abstract][Full Text] [Related]
19. CSF α-synuclein and UCH-L1 levels in Parkinson's disease and atypical parkinsonian disorders.
Mondello S; Constantinescu R; Zetterberg H; Andreasson U; Holmberg B; Jeromin A
Parkinsonism Relat Disord; 2014 Apr; 20(4):382-7. PubMed ID: 24507721
[TBL] [Abstract][Full Text] [Related]
20. Unbiased Proteomics of Early Lewy Body Formation Model Implicates Active Microtubule Affinity-Regulating Kinases (MARKs) in Synucleinopathies.
Henderson MX; Chung CH; Riddle DM; Zhang B; Gathagan RJ; Seeholzer SH; Trojanowski JQ; Lee VMY
J Neurosci; 2017 Jun; 37(24):5870-5884. PubMed ID: 28522732
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
